BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23939195)

  • 1. The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia.
    Bech PR; Martin NM; Ramachandran R; Bloom SR
    Ann Clin Biochem; 2014 Jan; 51(Pt 1):8-21. PubMed ID: 23939195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of the utility of Cocaine- and Amphetamine-Regulated Transcript (CART), chromogranin A, and chromogranin B in neuroendocrine tumor diagnosis and assessment of disease progression.
    Ramachandran R; Bech P; Murphy KG; Caplin ME; Patel M; Vohra S; Khan MS; Dhillo WS; Sharma R; Palazzo FF; Win Z; Tan T; Khoo B; Meeran K; Frilling A; Ghatei MA; Bloom SR; Martin NM
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1520-8. PubMed ID: 25664601
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurements of chromogranin B can serve as a complement to chromogranin A.
    Stridsberg M; Eriksson B; Fellström B; Kristiansson G; Tiensuu Janson E
    Regul Pept; 2007 Mar; 139(1-3):80-3. PubMed ID: 17116339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Routine measurement of plasma chromogranin B has limited clinical utility in the management of patients with neuroendocrine tumours.
    Monaghan PJ; Lamarca A; Valle JW; Hubner RA; Mansoor W; Trainer PJ; Darby D
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):348-52. PubMed ID: 26608723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated cocaine- and amphetamine-regulated transcript immunoreactivity in the circulation of patients with neuroendocrine malignancy.
    Bech P; Winstanley V; Murphy KG; Sam AH; Meeran K; Ghatei MA; Bloom SR
    J Clin Endocrinol Metab; 2008 Apr; 93(4):1246-53. PubMed ID: 18211969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms].
    Chen L; Chen M; Chen J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Mar; 20(3):357-360. PubMed ID: 28338171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
    Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limitations of Chromogranin A in clinical practice.
    Marotta V; Nuzzo V; Ferrara T; Zuccoli A; Masone M; Nocerino L; Del Prete M; Marciello F; Ramundo V; Lombardi G; Vitale M; Colao A; Faggiano A
    Biomarkers; 2012 Mar; 17(2):186-91. PubMed ID: 22303881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vasostatin-1: A novel circulating biomarker for ileal and pancreatic neuroendocrine neoplasms.
    Corsello A; Di Filippo L; Massironi S; Sileo F; Dolcetta Capuzzo A; Gemma M; Carlucci C; Cusini C; Colombo B; Dallatomasina A; Franchi GM; Corti A; Manzoni MF
    PLoS One; 2018; 13(5):e0196858. PubMed ID: 29723285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame.
    Marotta V; Zatelli MC; Sciammarella C; Ambrosio MR; Bondanelli M; Colao A; Faggiano A
    Endocr Relat Cancer; 2018 Jan; 25(1):R11-R29. PubMed ID: 29066503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine- and amphetamine-regulated transcript.
    Bech PR; Ramachandran R; Dhillo WS; Martin NM; Bloom SR
    Clin Chem; 2012 May; 58(5):941-3. PubMed ID: 22361937
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinicopathological hallmarks and biomarkers of colorectal neuroendocrine neoplasms.
    Koenig A; Krug S; Mueller D; Barth PJ; Koenig U; Scharf M; Ellenrieder V; Michl P; Moll R; Homayunfar K; Kann PH; Stroebel P; Gress TM; Rinke A
    PLoS One; 2017; 12(12):e0188876. PubMed ID: 29232390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogranin A and chromogranin B are sensitive circulating markers for phaeochromocytoma.
    Stridsberg M; Husebye ES
    Eur J Endocrinol; 1997 Jan; 136(1):67-73. PubMed ID: 9037129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granin-derived peptides as diagnostic and prognostic markers for endocrine tumors.
    Conlon JM
    Regul Pept; 2010 Nov; 165(1):5-11. PubMed ID: 19931574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chromogranin A--biological function and clinical utility in neuro endocrine tumor disease.
    Modlin IM; Gustafsson BI; Moss SF; Pavel M; Tsolakis AV; Kidd M
    Ann Surg Oncol; 2010 Sep; 17(9):2427-43. PubMed ID: 20217257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis.
    Malczewska A; Kidd M; Matar S; Kos-Kudła B; Bodei L; Oberg K; Modlin IM
    Neuroendocrinology; 2020; 110(3-4):198-216. PubMed ID: 31266019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Automated two-site immunofluorescent assay for the measurement of serum chromogranin A.
    Popovici T; Moreira B; Schlageter MH; Bories PN
    Clin Biochem; 2014 Jan; 47(1-2):87-91. PubMed ID: 24201067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective evaluation of the effect of chronic proton pump inhibitor use on plasma biomarker levels in humans.
    Raines D; Chester M; Diebold AE; Mamikunian P; Anthony CT; Mamikunian G; Woltering EA
    Pancreas; 2012 May; 41(4):508-11. PubMed ID: 22460728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromogranin A in diagnosing and monitoring patients with gastroenteropancreatic neuroendocrine neoplasms: a large series from a single institution.
    Massironi S; Rossi RE; Casazza G; Conte D; Ciafardini C; Galeazzi M; Peracchi M
    Neuroendocrinology; 2014; 100(2-3):240-9. PubMed ID: 25428270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms.
    Nielsen K; Binderup T; Langer SW; Kjaer A; Knigge P; Grøndahl V; Melchior L; Federspiel B; Knigge U
    BMC Cancer; 2020 Jan; 20(1):27. PubMed ID: 31924180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.